CAR NK cell therapy for solid tumors: potential and challenges
Antibody Therapeutics · 16.10.2025 · 8 (4) · 275-289
DOI: 10.1093/abt/tbaf019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 11.09.2025. Verfasst von Yanlin Yu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Antibody Engineering Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Intramural Research Program of the National Institutes of Health.
Abstract (Originalsprache)
CAR-T cell therapy has shown promise but is constrained by side effects and limited efficacy in treating solid tumors. Compared to CAR-T cells, CAR natural killer (NK) cells derived from multiple versatile sources exhibit more favorable safety profiles and possess the unique ability to refine cytotoxic activity, serve as off-the-shelf options, and target a broad range of tumors. However, several challenges still impede the development and implementation of CAR NK cell therapy for solid tumors. This review article outlines the therapeutic strategies, advantages, limitations, and potential solutions, while providing insight into the future landscape by challenging current knowledge in the field. It also discusses optimizing CAR NK cell structure, addressing obstacles in the clinical utility of CAR NK cell therapy, and integrating it into standard cancer treatment regimens. Ultimately, we aim to navigate the crucial challenges in treating solid tumors and explore the future of this approach.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Antibody Engineering Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
ORCID-Profile: Mitchell Ho
Förderung
- Intramural NIH HHS
- Intramural Research Program of the National Institutes of Health
Zitieren
APA
Yu, Y., & Ho, M. (2025). CAR NK cell therapy for solid tumors: potential and challenges. Antibody Therapeutics, 8(4), 275-289. https://doi.org/10.1093/abt/tbaf019
Vancouver
Yu Y, Ho M. CAR NK cell therapy for solid tumors: potential and challenges. Antibody Therapeutics. 2025;8(4):275-289. doi:10.1093/abt/tbaf019
BibTeX
@article{Yu2025,
author = {Yu, Yanlin and Ho, Mitchell},
title = {CAR NK cell therapy for solid tumors: potential and challenges},
journal = {Antibody Therapeutics},
year = {2025},
volume = {8},
number = {4},
pages = {275--289},
doi = {10.1093/abt/tbaf019}
}
EUVIMED